Recent Analysts’ Ratings Changes for Blueprint Medicines (BPMC)

Blueprint Medicines (NASDAQ: BPMC) has recently received a number of price target changes and ratings updates:

  • 10/18/2018 – Blueprint Medicines was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/17/2018 – Blueprint Medicines was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 10/9/2018 – Blueprint Medicines was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/8/2018 – Blueprint Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $101.00 price target on the stock.
  • 10/7/2018 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 9/25/2018 – Blueprint Medicines is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $105.00 price target on the stock.
  • 9/18/2018 – Blueprint Medicines is now covered by analysts at Guggenheim. They set a “buy” rating and a $102.00 price target on the stock.
  • 9/17/2018 – Blueprint Medicines was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 9/1/2018 – Blueprint Medicines was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/25/2018 – Blueprint Medicines was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

NASDAQ:BPMC opened at $69.69 on Friday. Blueprint Medicines Corp has a 12-month low of $57.44 and a 12-month high of $109.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.36 and a quick ratio of 12.36. The stock has a market capitalization of $3.10 billion, a P/E ratio of -17.78 and a beta of 1.08.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.32) by $0.70. Blueprint Medicines had a negative net margin of 326.99% and a negative return on equity of 32.61%. The firm had revenue of $41.40 million during the quarter, compared to analyst estimates of $2.62 million. During the same quarter in the prior year, the business posted ($0.86) earnings per share. The company’s quarterly revenue was up 602.9% compared to the same quarter last year. Equities analysts predict that Blueprint Medicines Corp will post -5.15 EPS for the current fiscal year.

In related news, insider Marion Dorsch sold 2,300 shares of the stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $70.47, for a total value of $162,081.00. Following the completion of the transaction, the insider now owns 2,300 shares of the company’s stock, valued at $162,081. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey W. Albers sold 20,000 shares of the stock in a transaction dated Monday, August 6th. The stock was sold at an average price of $70.59, for a total transaction of $1,411,800.00. Following the completion of the transaction, the chief executive officer now directly owns 20,000 shares of the company’s stock, valued at approximately $1,411,800. The disclosure for this sale can be found here. Corporate insiders own 3.15% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. FMR LLC raised its position in Blueprint Medicines by 0.7% in the second quarter. FMR LLC now owns 6,575,600 shares of the biotechnology company’s stock worth $417,419,000 after purchasing an additional 44,401 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Blueprint Medicines by 1.9% during the second quarter. BlackRock Inc. now owns 3,321,905 shares of the biotechnology company’s stock worth $210,876,000 after buying an additional 63,392 shares in the last quarter. OppenheimerFunds Inc. increased its holdings in shares of Blueprint Medicines by 4.0% during the second quarter. OppenheimerFunds Inc. now owns 1,677,731 shares of the biotechnology company’s stock worth $106,503,000 after buying an additional 64,095 shares in the last quarter. Hillhouse Capital Management Ltd. increased its holdings in shares of Blueprint Medicines by 4.6% during the second quarter. Hillhouse Capital Management Ltd. now owns 1,430,949 shares of the biotechnology company’s stock worth $90,837,000 after buying an additional 62,500 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Blueprint Medicines by 0.6% during the second quarter. Northern Trust Corp now owns 499,911 shares of the biotechnology company’s stock worth $31,735,000 after buying an additional 2,776 shares in the last quarter. 99.76% of the stock is owned by hedge funds and other institutional investors.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Featured Story: What is the Dividend Aristocrat Index?

Receive News & Ratings for Blueprint Medicines Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply